Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Voorraadrapport

Marktkapitalisatie: US$2.1b

Supernus Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Supernus Pharmaceuticals heeft een totaal eigen vermogen van $1.0B en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $1.3B en $335.6M. De EBIT Supernus Pharmaceuticals is $60.8M waardoor de rentedekking -4.6 is. Het heeft contanten en kortetermijnbeleggingen van $403.2M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio-4.6x
ContantUS$403.21m
AandelenUS$1.01b
Totaal verplichtingenUS$335.55m
Totaal activaUS$1.34b

Recente financiële gezondheidsupdates

Recent updates

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $640.0M ) SUPN } overtreffen de korte termijn passiva ( $291.5M ).

Langlopende schulden: De kortetermijnactiva SUPN ( $640.0M ) overtreffen de langetermijnschulden ( $44.0M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: SUPN is schuldenvrij.

Schuld verminderen: SUPN heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 65.4% was.

Schuldendekking: SUPN heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: SUPN heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.


Balans


Ontdek gezonde bedrijven